AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00097786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg + valsartan placebo
Description: The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
Study NCT00097786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsartan placebo + nateglinide placebo
Description: The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
Study NCT03743246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JCAR017
Description: JCAR017
Study NCT03743246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting
Description: Lymphodepleting
Study NCT03743246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine
Study NCT03743246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide
Study NCT04505943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isonicotinic Acid Hydrazide
Description: 2 vaginal tablet of isonicotinic acid hydrazide inserted by the study nurse12 hours before IUD insertion.
Study NCT04505943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dinoprostine
Description: 2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
Study NCT04505943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: 2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion
Study NCT00979056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 400 mg per day, oral use, maximum duration 28 days
Study NCT00979056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: Coated Tablet, Oral Use
Study NCT01490580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atropine+ propofol
Description: Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
Study NCT01490580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atropine + atracurium + sufentanil
Description: Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants > 1000g
Study NCT04666818 — intervention group
Intervention type: DEVICE
Intervention: Use of Flash Glucose Monitoring
Description: Participants in the intervention group were advised to monitor glucose levels by means of flash glucose system.
Study NCT03890640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided TECI
Description: When performing an ultrasound-guided thoracic epidural catheter insertion (TECI), an 18-gauge Tuohy needle will be used for interlaminar epidural access. All procedures will be performed with a paramedian approach under ultrasound-guidance and using the loss of resistance technique with saline. If the needle is deemed to be in the epidural space when the loss of resistance occurred, fluoroscopic views will be obtained to confirm which the catheter tip is located in the epidural space or not.
Study NCT04679519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drop Jumps
Description: Perform 100 drop jumps from 40 cm height. The protocol is divided into 5 sets of 20 repetitions. Between each repetition participants get 10 seconds, and between each set 2 minutes rest. Stand on the box, drop of the box and land with feet shoulder width apart. Then immediately bend knee to approx 45 degrees and jump straight up. Throughout each jump hands are placed on hips and should not move.
Study NCT04679519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drop Jumps
Description: Perform 100 drop jumps from 40 cm height. The protocol is divided into 5 sets of 20 repetitions. Between each repetition participants get 10 seconds, and between each set 2 minutes rest. Stand on the box, drop of the box and land with feet shoulder width apart. Then immediately bend knee to approx 45 degrees and jump straight up. Throughout each jump hands are placed on hips and should not move.
Study NCT03502317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Prehabilitation
Description: Physical prehabilitation will comprise a personalized, home-based exercise program designed to meet the Cancer Care Ontario Exercise Guidelines for Cancer Survivors. A Registered Kinesiologist (RKin) will complete a baseline physical assessment and prescribe an individualized multi-modal exercise program consisting of 4-5 days of 30+ minutes of aerobic exercise (brisk walking or equivalent to target heart rate of 40-60% of max) and 2-3 days of moderate intensity resistance training of major muscle groups (8-10 repetitions). Participants will be provided with a Fitbit with a heart rate monitor, resistance bands, and a stability ball. Patients will be required to wear their Fitbit and record the number of steps at the end of each day from randomization to 90 days post-surgery.
Study NCT03502317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Prehabilitation
Description: Psychological prehabilitation will consist of one in-person coaching session of a 'mindfulness' informed intervention conducted by a specially trained RKin. The 40 minute coaching session will include a guided mindfulness session and debriefing. Participants will be asked to practice for 20 minutes twice a day. The patients will be given access to an audio file that will walk them through the 20 minute sessions.
Study NCT02961127 — intervention group
Intervention type: OTHER
Intervention: Venous blood was collected
Description: Venous blood was collected by standard vein puncture in fasting condition
Study NCT03835390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIMDiscovery
Description: The SIMDiscovery program consists of nine stations that were designed to mirror the different stages of the perioperative process. The stations mirror the different stages of the surgical process and provide patients and their families with education regarding what they can anticipate during each aspect of the intervention.
Study NCT03782480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrarosa
Description: Prasterone intravaginal inserts
Study NCT03782480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo intravaginal inserts
Study NCT04438850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Patients will be administered a single oral daily dose of approximately 600 μg/Kg (486-679 μg/Kg as rounded to a whole number of tablets), or 1200 μg/Kg (1098-1286 μg/Kg).
Study NCT04438850 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients should take placebo orally on an empty stomach with water
Study NCT04302155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance-specific -games focusing on dynamic aspects of COP on Wii fit system.
Description: The participants were randomly assigned into two groups interventional and control. Total 18 minutes session was given to both groups wii fit group and traditional balance training group. All participants were given 3 sessions per week for 6.~Total 48 participants were initially accessed initially for eligibility , 13 participants were excluded because of having good balance and good balance age score on Wii fit assessment, 35 participants were recruited for balance training. These participants were randomly divided into Wii fit and traditional training group through sealed enveloped method 18 participants was recruited in Wii fit group and 17 in traditional balance training group. 3 participants drop out from Wii fit group and 2 from traditional balance training group.~Some examples include catching apples in a basket ,moving a golf ball around barriers towards a hole , popping rising balloons/bubbles and air hockey .
Study NCT04302155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mini trampoline and inflatable discs group
Description: High skipping and landing on a limb every time (2 repeats of 45 s each leg).Standing on one leg and try to catch the ball thrown at them in various directions by the researcher (2 repeats of 45 s each leg) Exercises in inFlated rubber hemisphere attached toa rigid platform (BOSU)~1. Standing on BOSU's round soft surface with one foot, in an attempt to maintain balance (2 repeats of 45 s each leg).~2. Standing on BOSU's round soft surface with one foot, in an attempt to maintain balance, while lifting the non-support leg forward and backward (2 repeats of 45 s each leg).~3. Standing on BOSU flat hard surface with both legs, in an attempt to maintain balance (3 minutes on both legs).~4. Standing on BOSUs flat hard surface with both feet, in an attempt to maintain balance, while trying to catch the ball thrown at them by the experimenter in various directions (3 minutes on both leg)
Study NCT04083833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrodotoxin
Description: A single TTX dose in a dose ascending study
Study NCT03199079 — intervention group
Intervention type: OTHER
Intervention: Measurement
Description: Measurement of cervix elasticity and length measurements is not an intervention
Study NCT02210676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS Upper Extremity
Study NCT02210676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Likert Pain Scale
Study NCT02210676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mallet Finger Extensor Lag Measurement
Study NCT04083833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: matching placebo comparator
Study NCT02533635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A Master Ganoderma Detox Tea
Description: A Master Ganoderma Detox Tea is consisted of GANODERMA, HERBA HOUTTUYNIAE, GLYCYRRHIZAE RADIX ET RHIZOMA and RUCTUS MOMORDICAE.
Study NCT03215251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention bundle
Description: Assessment of the patient's mouth and lips determined, to check any stickiness or dryness in the mouth or around lips or split skin at the corners of the mouth or cracked lips. Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered for in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
Study NCT03478696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide/formoterol
Description: Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
Study NCT00021216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00021216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00021216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00823199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinal
Description: 300mg once daily by mouth for four weeks
Study NCT03777345 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cobalt-chromium framework partial dentures
Description: It's a biocompatible metal alloy used in thin sections and are less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and is resistant to corrosion. Disadvantages include hypersensitivity, esthetic issues with metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production .
Study NCT03777345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK framework partial dentures
Description: It's a promising polymer-based framework material has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
Study NCT00707434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian® blood-sugar monitoring device
Description: The device has a small catheter that will be inserted subcutaneous tissue of the subject's abdomen or thigh set to continuously monitor glucose throughout the ICU stay for up to 15 days.
Study NCT03478696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol
Description: Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
Study NCT03478696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol/salbutamol
Description: Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
Study NCT03478696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
Study NCT03478696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
Study NCT03478696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match budesonide/formoterol
Description: Subjects will be administered two inhalations of matching placebo twice daily via MDI
Study NCT03478696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
Study NCT03478696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
Study NCT01960868 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard physiotherapy
Study NCT01960868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental physical therapy
Study NCT01450241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early antibiotic discontinuation
Description: Antibiotic treatment for unexplained febrile neutropenia stopped after 72 hours, regardless of fever
Study NCT01450241 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual practice
Description: Continued antibiotic treatment as accepted by guidelines for febrile neutropenia
Study NCT05164913 — intervention group
Intervention type: OTHER
Intervention: Achenbach Child Behavior Checklist （CBCL）scale
Description: Use the Achenbach Child Behavior Checklist （CBCL）scale to assess children's behavior
Study NCT03478696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match FF/UMEC/VI
Description: Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
Study NCT01839123 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic Suction or Pin Socket
Description: Conventional prosthetic socket utilizing non-vacuum suspension to secure the residual limb to the prosthesis. Non-vacuum suspension includes pin/lock suspension and suction suspension.
Study NCT01839123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic LimbLogic Vacuum Socket
Description: Prosthetic socket that incorporates conventional vacuum suspension using the commercially available LimbLogic vacuum pump
Study NCT02440035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.RSV.FA2
Description: Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 85 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 169 in Group 2. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 in Group 3.
Study NCT02440035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.FA2
Description: Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on Day 169 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 3. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 4.
Study NCT02440035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive intramuscular injection of placebo (sterile formulation buffer) on Day 85 in Group 2. One intramuscular injections of placebo on Day 85 in Group 3. Two intramuscular injections of placebo on Day 1, and Day 85 in Group 4.
Study NCT02771106 — intervention group
Intervention type: OTHER
Intervention: neuro vision rehabilitation
Description: Neuro vision rehabilitation used to treat vision dysfunction following TBI
Study NCT01226537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taurine
Description: 500 mg taurine capsules twice per day for 6 months
Study NCT01226537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Taurine
Description: 500 mg taurine capsules twice per day for 6 months
Study NCT03478696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to match tiotropium
Description: Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
Study NCT03478696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELLIPTA
Description: Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
Study NCT03478696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
Study NCT03478696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MDI
Description: Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
Study NCT03478696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDI
Description: Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
Study NCT01353807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: 4 1-g gelatine capsules per day providing 2,7 grams long chain n-3 fatty acids
Study NCT01353807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: 4 1-g gelatine capsules with virgin olive oil
Study NCT03576287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Oral Product
Description: Apremilast
Study NCT03478696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HandiHaler
Description: Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
Study NCT03478696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HandiHaler
Description: Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
Study NCT04067960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of saliva
Study NCT04067960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Undergo pharmacogenomics testing
Study NCT04067960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01468155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dabigatran
Description: 30 days pre ablation and 90 days post ablation
Study NCT00656370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human hyaluronidase
Description: 150 Units in 1mL
Study NCT01090947 — intervention group
Intervention type: DEVICE
Intervention: ProtoCAD
Description: Aquiring acoustic signals from heart patients.